Research Studies

The primary goal of the Mental and Substance Use Disorder Prevalence Study (MDPS) is to provide national estimates of mental health and substance use disorders among U.S. adults ages 18 to 65. These include schizophrenia, schizoaffective disorder, bipolar disorder, major depression, posttraumatic stress disorder, obsessive-compulsive disorder, generalized anxiety disorder, and alcohol, benzodiazepine, opioid, stimulant, and cannabis use disorders. The study is also designed to estimate what proportion of individuals with mental and substance use disorders receive treatment. A secondary goal of the MDPS is to consider the best research methods for doing studies like this in the future. Study findings will help determine the treatment and service needs for mental health and substance use disorders and inform policies and service funding decisions.

We are seeking participants aged 18 or older who have received services from a mental health professional in the past 12 months to help us prepare our clinician interviewers before the start of the full study’s data collection. These interviews will be conducted virtually by web and video. The interview is approximately 60 to 90 minutes, depending on the disorders endorsed. Study participants will receive a $30 gift card upon completion of a full interview. Recruitment and interviews will run through early 2021.

Visit this website to complete the screener: http://survey.rti.org/SE/1/CIEQ

Reach out to the research team at: nsmh@rti.org or 833-947-2575 if you have questions.

Dr. Diane Gooding, from UW-Madison and NAMI-Dane County, is looking for participants for a research study.

This study is about the social and psychological effects of COVID-19 on people who have pre-existing mental health conditions. If you take part in this study, you would take an online survey for approximately 60 – 75 minutes and answer questions about your diagnosis, mental health, treatment, thoughts, feelings, and beliefs about COVID, and your living situation before and since the pandemic started.

To be able to take part in this study, individuals must be over age 18 and be diagnosed by a health care professional. Participation in this study is anonymous and entirely voluntary; you won’t get paid. However, we hope that what we learn can help shed some light on the needs of people with lived experience and provide scientific evidence to support the need for expanded services.

If you have questions about the study, please email: pathsresearch@psych.wisc.edu

If you’d like to participate, here’s the link: https://uwmadison.co1.qualtrics.com/jfe/form/SV_9uGbsLluhexQ3VH

Post expires: August 2021

The purpose of this study is to investigate the relationship between aging processes and PTSD, which may help identify novel therapeutic targets to promote healthier aging trajectories for PTSD patients. Chronic PTSD increases mortality risk from medical diseases, promotes aging-associated syndromes such as frailty, and is linked to faster cognitive decline in older adults. One strong possibility is that PTSD leads to these adverse health outcomes by accelerating biological aging in the brain and body.

Participants will be asked to attend a total of 3 visits consisting of: an evaluation, an MRI, and a day of neuropsychological testing.

To participate, individuals must be 50 years or older. This study is enrolling healthy control volunteers.

To compensate for the time required for the eligibility evaluation, we offer $50 cash upon completion. Additionally, you will be paid $300 if you complete all procedures in this study, including the two additional study visits. Payment will take place in the form of a check.

A person to contact, and a website for more general information.

Nicolas Cimino at 646-774-8655 or nicolas.cimino@nyspi.columbia.edu

https://recruit.cumc.columbia.edu/clinical_trial/1649

When does the post expire? Two years

The purpose of this study is to determine whether treating hearing loss is helpful for depression over and above the known effects of antidepressants. Age-related hearing loss (ARHL) is the third most common health condition affecting older adults after heart disease and arthritis and is the fifth leading cause of years lived with disability worldwide. Many hearing-impaired older adults avoid or withdraw from social contexts in which background noise will make it difficult to communicate, resulting in social isolation and reduced communication with family and friends. Social isolation and loneliness have been linked to numerous adverse physical and mental health outcomes, including dementia, depression, and mortality, and they may also lead to declining physical activity and the development of the syndrome of frailty.

In this research study, participants may be fitted with free hearing aids. They will also receive treatment for depression with an FDA approved medication called escitalopram (Lexapro) or duloxetine (Cymbalta). Escitalopram is a Selective Serotonin Reuptake Inhibitor (SSRI) medication, and duloxetine is a Selective Serotonin-Norepinephrine Reuptake Inhibitor (SSNRI) that both appear to help with symptoms of depression. Participants will attend study visits to monitor progress and ensure safety over the course of participation. Participants may also be offered brain scans using magnetic resonance imaging (MRI).

To participate, individuals must be 60 years or older.

We offer $50 for the completion of each MRI scan. We also offer reasonable compensation for travel costs related to study participation. Participants may also receive free hearing aids listed at a price of $6000.

A person to contact, and a website for more general information.

Carlen Zhu at 646-774-8005 or Carlen.zhu@nyspi.columbia.edu

https://recruit.cumc.columbia.edu/clinical_trial/1323

This post expires in one year.

Individuals with Late Life Depression (LLD) often have problems with memory, attention, and problem solving, all of which contribute to antidepressant non-response. Available evidence suggests that declining functionality in the brain’s dopamine system contributes to age-related cognitive and motor slowing. The purpose of this research study is to test whether a medication called carbidopa/levodopa (Sinemet) is helpful for the treatment of depression in older adults. Carbidopa/levodopa is approved by the Food and Drug Administration for the treatment of Parkinson’s Disease. We are using carbidopa/levodopa in this study to see whether it is capable of improving depressive symptoms as well as mental and physical slowing that occur as people age.

Participants will be prescribed carbidopa/levodopa (Sinemet) by the study psychiatrist, free of charge. Progress will be monitored through weekly visits with the study staff for 8 weeks. Participants may also be offered brain scans using magnetic resonance imaging (MRI) and positron emission tomography (PET).

To participate, individuals must be 60 years or older.

Subjects are compensated $15 for each weekly study visit ($135 total if they attend all visits). This money will be paid by cash at the conclusion of each of these visits.

To compensate for the time required for the brain scans, we offer $50 for each MRI scan and $150 for each PET scan ($400 total if all visits are attended). This money will be paid in 1 lump sum payment at the end of the study.

A person to contact, and a website for more general information.

Marika Chrisanthopoulos at 646-774-8697 (marika.chrisanthopoulos@nyspi.columbia.edu)

https://recruit.cumc.columbia.edu/clinical_trial/1586

Post expires in one year.

Treatment-resistant depression (TRD) is a major health problem for the growing population of older adults. Unfortunately, there is a lack of evidence-based treatments that establish the benefits vs. risk of medication in this patient population. The purpose of this research study is to find out which antidepressants work best in individuals over the age of 60 who did not respond or were intolerant to at least two antidepressant medications. The study offers treatment with FDA approved medications: aripiprazole, bupropion, lithium, and nortriptyline.

Participants will be prescribed medication by the study psychiatrist. Progress will be monitored through biweekly phone calls or visits with the study staff. Participants will be asked to complete neuropsychological assessments, answer questions about their mood, and report medication tolerance.

To participate, individuals must be 60 years or older.

Subjects are paid $50 for completing initial evaluation. If found eligible and enrolled into the study, subjects receive $75 at the baseline visit, $75 at the end of 10-weeks of treatment, and $25 at each of 3 follow up visits after completing the initial 10 weeks of acute treatment.

A person to contact, and a website for more general information.
Johana Alvarez at 646-774-8664 (johana.alvarez@nyspi.columbia.edu) or Esteban Ceballos for service in Spanish at 646-774-8670 (esteban.ceballos@nyspi.columbia.edu)

https://recruit.cumc.columbia.edu/clinical_trial/953

Study will continue to recruit for the next 2 years.

The purpose of this 8-week study is to evaluate the effectiveness of a medication called tianeptine for treating depression in people whose symptoms have not responded to two prior treatments.

To participate, individuals must be between the ages of 21-50 and must have tried at least two antidepressant medications without complete success. Individuals can receive up to $1000 over the course of participation.

For more information, contact Sara Fernandez at 646-774-8698 or sara.fernandez@nyspi.columbia.edu.

Go here to apply: https://recruit.cumc.columbia.edu/clinical_trial/2008

This post expires in 2023.

The purpose of this study is to explore whether a specific therapy that provides psychoeducation to people who are at risk for psychosis is effective and acceptable. This study involves completing an interview about your symptoms and experiences to determine if you are eligible. If you are eligible, you will participate in five 1-hour sessions of a psychoeducational therapy, and complete questionnaires and interviews at two time points (before and after the therapy) to gather more information about your symptoms and experiences. During the COVID-19 pandemic and when social distancing requirements are in place, study visits may take place over a HIPAA-compliant and free telehealth platform.

Subjects will be compensated $10 per visit, and an additional $15/hour at each of the two evaluation sessions.

Please contact Dr. Shaynna Herrera at shaynna.herrera@mssm.edu. More information can be found here:

https://www.cuemountsinai.org

https://www.mountsinai.org/care/behavioral-health/services/schizophrenia/psychosis-risk

When does the post expire? July 2021

We are conducting this study to discover if there is an intersection between psychosis causing a form of trauma for those experiencing it. The participants will fill out a survey about their experiences. There will be an optional second part that includes being interviewed, but that is something individuals will opt into voluntarily at the end of the survey.

Eligibility: anyone who has or is actively experiencing psychosis.

Every 10th participant will be compensated with $50 up to 5 gift cards.

Click here to begin the survey: https://usf.az1.qualtrics.com/jfe/form/SV_42FdB0vsReyHSUR

If you have any further questions, please contact Shannon Pagdon at ShannonPagdon@gmail.com or by phone at (347) 768-2721.

There is no current expiration for the survey. We are looking for at least 100 participants, so however long it takes to get there will be the determining factor.

Social function relies on language and communication between individuals and others. This includes speaking in a way that makes it easy for people to understand what we are saying, and also being able to read other people’s emotions and intentions in their speech and facial expression.

For many people who have had psychotic-like experiences, they have some struggles with getting their point across, or in understanding what others intend to communicate. So far, there are no interventions that can clearly help people with such symptoms with communication and social function. The purpose of this study is to better understand difficulties with language and social cognition, so that interventions can be developed to improve these.

Our study is designed for individuals between the ages of 15 and 35 who have had psychotic-like experiences. Such experiences include unusual thoughts, suspiciousness, and/or perceptual disturbances, like hearing one’s name in the wind or colors looking different. This study is also available to individuals who have a psychosis diagnosis.

The study involves interviews, computer tests, and brain scans using both magnetic resonance imaging (MRI), which creates pictures of the brain, and electroencephalography (EEG), which records brain waves. Many study visits can take place using a videochat platform for which privacy is maintained. All participants are offered a copy of their initial evaluation.

Who will be conducting the study? Icahn School of Medicine at Mount Sinai

Will subjects be paid (include payment schedule)? Yes. The payment schedule is

1) $70 total for interview and tests;
2) $50 for EEG; and
3) $100 for each of the two MRI sessions, for a total of $200 for MRI.
4) $30 for six-month follow-up visits for interview of 1-2 hours

Please contact Dr. Shaynna Herrera at shaynna.herrera@mssm.edu. More information can be found here:

https://www.cuemountsinai.org

https://www.mountsinai.org/care/behavioral-health/services/schizophrenia/psychosis-risk

When does the post expire? June 2021

The purpose of this study is to determine if taking a pill of estradiol (a form of estrogen) together with prolonged exposure (PE) therapy can improve this treatment outcome in women with Post-Traumatic Stress Disorder (PTSD). Prolonged Exposure (PE) therapy is a validated, evidence-based talk therapy that focuses on helping individuals with PTSD process memories of the trauma. Based on previous findings that the hormone estrogen facilitates people learning not to fear things they had feared before, we want to supplement prolonged exposure therapy with an estradiol pill given before each therapy session. Participants will be randomly assigned to either take estrogen or a placebo (which looks just like the estrogen pill but contains no medicine). Participants will not know which pill they are taking. As part of this study, participants will be asked to go through two separate fMRI scans, one before prolonged exposure therapy treatment and one after. This machine is routinely used by scientists to study the brain and does not use any radiation (x-rays).

The study involves 12 visits to our lab, which is located in midtown east Manhattan, over the course of a 6-9-week period. These visits can be broken down into 2 experimental days, 6 prolonged exposure therapy sessions, and 2 more experimental days. Participation in this study requires 12 visits over six weeks. Six of these visits will be therapy sessions. The other 6 days include assessment visits and going through an emotional learning and memory task before and after therapy. Participants will undergo a fear conditioning procedure that involves receiving an annoying but not painful, half-second electric current applied to the fingers. This procedure will be conducted during two consecutive days. The second day will be conducted in an fMRI scanner. Participants will be paid for their time. Blood samples will be gathered at different time points of the study. There will also be follow-up visits at 3 months and 6 months.

Eligibility criteria: Females between the ages of 18-45 who are taking an oral contraceptive (i.e., birth control)

Is the study therapeutic? Yes – participants will receive free Prolonged Exposure therapy no matter which study arm they are assigned to (i.e., placebo vs estradiol pill).

Is the study funded? Yes, this study is funded by the National Institute of Mental Health (NIMH)

Who will be conducting the study? The study is being conducted at two different sites: Dr. Mohammed Milad is conducting the study within the Department of Psychiatry at NYU Langone Health, and Dr. Edna Foa is conducting the study within the Department of Psychiatry at the University of Pennsylvania Perelman School of Medicine.

Will subjects be paid? Yes – The total compensation for all completed parts will be 480 dollars. Participants will receive 10 dollars for each study visit from visits 1-11 to help defray costs of travel and time. Participants will then receive 270 dollars upon completion of visit 12.

Participants will receive 50 dollars at each remaining follow-up visit. Participants who drop out of the study will be paid for the visits they attended.

Contact information: For more information regarding the study, you can call 1-888-44-WORRY or email Behavioralneuroscience@nyulangone.org. You can also complete the online pre-screening by following this link: https://is.gd/NYU_PTSD_STUDY and a research coordinator will reach out to you with further information about the study.

Post Expiration: The study will be recruiting until June 2023

Synexus is performing this study to test study medication that may help individuals aged 18 to 60 years of age, who have been diagnosed with schizophrenia, are experiencing negative symptoms of schizophrenia, and have been clinically stable for at least 6 months. Those who qualify for this study will be performing multiple things like attending 7 visits over a 6-month period, answer questions about their health, obtain blood work and get a physical, and potentially asked to keep a diary throughout the study. The study is therapeutic as there will be study medication at no cost to you. This study is funded by the pharmaceutical company that provides the study medication. Our physicians at Synexus in Queens, New York will be conducting the study at no cost to you. Additionally, compensation for study-related time and travel may be available. For more information, feel free to call Synexus at 718-873-3804, reach out on our Synexus US (Queens) Facebook, or go to our website at www.synexusclinic.com/our-clinics/synexus-queens/.

This post expires 02/20/2021.

Synexus is performing this study to test study medication that may help individuals aged 18 to 65 years of age, who have been diagnosed with schizophrenia, been prescribed and are currently taking an antipsychotic medication treatment for at least 6 months, and have had an inpatient hospitalization for schizophrenia within the last 4 years. Those who qualify for this study will be performing multiple things like attending 6 visits over a 6-month period, answer questions about their health, get a physical, and potentially asked to keep a diary throughout the study. The study is therapeutic as there will be study medication at no cost to you. This study is funded by the pharmaceutical company that provides the study medication. Our physicians at Synexus in Queens, NY will be conducting the study at no cost to you. Compensation for study-related time and travel may be available. For more information, feel free to call Synexus at 718-873-3804, reach out on our Synexus US (Queens) Facebook, or go to our website at www.synexusclinic.com/our-clinics/synexus-queens/.

This post expires 02/20/2021.

The purpose of this outpatient study is to determine the safety and effectiveness of an oral investigational medication, versus placebo, combined with cognitive therapy, for adults with schizophrenia. Those who qualify for this study will be performing multiple things like attending 6 visits up to 20 weeks in duration, answer questions about their health, obtain blood work and get a physical, and potentially asked to keep a diary throughout the study. The study is therapeutic as there will be study medication at no cost to you. This study is funded by the pharmaceutical company that provides the study medication. Our physicians at Synexus Queens, New York will be conducting the study at no cost to the patient. Additionally, compensation for study-related time and travel may be available. For more information, feel free to call Synexus at 718-873-3804, reach out on our Synexus US (Queens) Facebook, or go to our website at www.synexusclinic.com/our-clinics/synexus-queens/.

This post expires 02/20/2021.

This study is a clinical trial of the medication miricorilant. The trial will assess if miricorilant is a safe and effective treatment to reduce body weight in adults with schizophrenia who have gained weight as a result of their antipsychotic medication. The trial will also measure physical health indicators like insulin resistance. The goal of this study is to give people with schizophrenia more options for treatment and management of their physical health.

WHO CAN PARTICIPATE?

Participants may be eligible for this study if they:

• Are between the ages of 18 and 65
• Have a diagnosis of schizophrenia
• Have a BMI (body mass index) of 30 kg/m2 or greater
• Are currently taking the antipsychotic medications olanzapine, risperidone, or quetiapine; and have experienced weight gain while taking the medication

WHERE IS THE STUDY TAKING PLACE?

The study will take place at multiple sites across the United States. There is one site currently recruiting in your area, in: Brooklyn, NY

For a list of sites, please refer to the posting on clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT03818256

HOW DO I LEARN MORE?

For more information, please refer to the posting on clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT03818256

Or contact the study sponsor at study876ctgov@corcept.com.

This study is an anonymous online survey for adults with a mental health condition and their family members/caregivers. The goal of the survey is to understand how much people know about the physical health risks related to mental health conditions and treatments. The survey will ask questions about the participant’s knowledge of physical health and about the care they have received from health care providers. This study will help health care providers improve the ways they educate and support people with mental health conditions.

The study is being conducted by researchers at the University of Massachusetts Lowell and McLean Hospital. The survey takes 15-20 minutes to complete.

Participants may be eligible for this study if they are:

• Aged 18 or older
• Have a mental health condition, or are the family member/ caregiver of a person with a mental health condition

The survey is available online. To access the survey please use the following link: https://umasslowell.co1.qualtrics.com/jfe/form/SV_80MfUYLoMqduzvD

HOW DO I LEARN MORE?
If you have questions or would like more information, please contact the researchers at (978) 934-4471 or Margaret_Knight@uml.edu.

This study is an anonymous online survey being conducted by Dr. Eric Storch, PhD, at the Baylor College of Medicine. The goal of the study is to better understand participants’ thoughts and feelings about Deep Brain Stimulation (DBS) as a treatment option for severe Obsessive Compulsive Disorder (OCD) in adolescents. Understanding the thoughts and feelings of adults with OCD, and of parents who have children with OCD, will support researchers working to improve treatment options in the future.

Individuals may be eligible for this study if they are:

• Adults (aged 18+) with OCD
• Parents (aged 18+) of children with OCD

This study is a 10-15 minute anonymous online survey. Interested individuals can access the survey at this link: https://bcmpsych.sjc1.qualtrics.com/jfe/form/SV_8BQ8l5Q5Sar6dP7.

An introductory letter from the researchers is available via the survey link: https://bcmpsych.sjc1.qualtrics.com/jfe/form/SV_8BQ8l5Q5Sar6dP7.

If you have questions, you may contact the research team at weinzimm@bcm.edu or (713) 798-8563.

Description: Researchers at the Icahn School of Medicine at Mount Sinai are looking for adults with Panic Disorder, Generalized Anxiety Disorder and/or Post-traumatic Stress Disorder to participate in a brain imaging study. Study investigators hope to learn how the brain is affected by stress and anxiety using new brain imaging technology.

You may be eligible to participate in this study if you:

• Are 18-55 years old
• Have Panic Disorder, Generalized Anxiety Disorder (GAD) or Post-Traumatic Stress Disorder (PTSD)

Participation in this research study includes a study screen and brain scan using magnetic resonance imaging (MRI), which can be done over 1-3 visits. Each study visit is expected to last approximately 2 – 5 hours in length. Subjects will be compensated for their participation.

Contact: If you are interested in participating, please take our online pre-screen at https://redcap.mountsinai.org/redcap/surveys/?s=VionGV8Bjh.

This study will expire in January 2024.

Looking for voluntary research participants who fit the following criteria:

• male or female between 18 and 65 years old
• diagnosed with schizophrenia or schizoaffective disorder

The purpose of this study is to study the effectiveness, safety and tolerability of different doses and durations of an investigational treatment called TV-46000 given by subcutaneous (under the skin) injection as compared to placebo for use as a potential maintenance treatment. TV-46000 is a risperidone extended-release injectable suspension for subcutaneous (sc) use that will deliver therapeutic levels of risperidone over intervals of 1 month (q1m) or 2 months (q2m) to patients with schizophrenia. TV-46000 is a new formulation of risperidone that uses a sustained-delivery technology. TV-46000 is intended to maintain enough levels of risperidone in your body for 1 or 2 months following a single subcutaneous injection. With the injections, a small “depot” of study medication is created under the skin and then the medication is slowly released over time. This is a potential advantage over the currently available two-week injectable form of risperidone. The purpose of the study is to compare the safety and efficacy of different durations of TV-46000 administered subcutaneously versus placebo.

Noncompliance and high discontinuation rates are particularly problematic in patients with schizophrenia. Premature discontinuation of antipsychotic drug therapy is a common phenomenon; in one large study comparing the best available oral medications, 74% of patients discontinued their antipsychotic drug within 18 months due to either poor tolerability or lack of efficacy. Even among patients who do not explicitly discontinue drug therapy, nonadherence to long-term oral medication regimen is one of the most significant therapeutic issues in the therapy of schizophrenia and related disorder. As a result, many of these patients do not experience the full benefit of antipsychotic drug
therapy and suffer frequent relapses or exacerbations that require rehospitalization, often in the context of psychiatric emergency. Thus, the use of a long-acting injectable (LAI) antipsychotic agent may increase compliance in patients with schizophrenia (PSF).

You will receive oral risperidone for 12 weeks and then be randomized (like flipping a coin) to TV- 46000 or placebo. Whether you receive TV-46000 or placebo is decided by chance. You will not learn during the study whether you received TV-46000 or placebo. The study is divided into 3 main parts: Pretreatment, Double-blind Maintenance, and Follow-up/Exit. Pretreatment Period includes the Screening and Stage 1 (Oral Conversion and Stabilization Stage) which has 5 visits and lasts up to 16 weeks. There is an initial screening visit to assess your medical and psychiatric history and symptoms of schizophrenia. You will have a physical exam and blood and urine will be obtained. After you start the study medication, we will monitor your schizophrenia symptoms and overall health throughout the study. You will have visits every 2 weeks during the Pretreatment Period and every week for 12 weeks and then every four weeks thereafter during the Double-Blind Maintenance Stage (open-ended, variable length). Study exit/follow up consists of two visits over 8 weeks.

You will not receive any payment for taking part in the study. To compensate you for your lost productivity associated with attending study visits, we will provide you with a stipend. You will receive a screening stipend in the amount of $75.00 paid via cash. Starting at visit 2, you will receive $75.00 for each clinic visit to compensate for expenses directly related to participation in the Study (such as transportation, meals and parking fees) and $30 for each telephone contact visit through the Greenphire Debit card reimbursement. The stipend for the clinic visits also will serve as reimbursement for travel expenses related to your participation in this study. You do not have to complete the study in order to receive reimbursement for your travel expenses. You will be reimbursed after each completed visit.

Person to Contact: if you have questions or if you would like to participate in this study call 646-774-8496 or e-mail melissa.conant@nyspi.columbia.edu.

When does the study expire?: Data collection for this study began in September 2018 and is scheduled to end in September 2021.

Looking for voluntary research participants who fit the following criteria:

• male or female between 18 and 60 years old
• diagnosed with schizophrenia or schizoaffective disorder
• having side effects or not doing well on current medications

This study plans to learn more about an investigational new drug called ITI-007 (lumateperone tosylate) and may help us to find new types of treatment for schizophrenia and schizoaffective disorder. “Investigational” means that the study drug (ITI-007) has not been approved by the U.S. Food and Drug Administration (FDA), and is considered experimental. There is no placebo (sugar pill) in this study, and everyone will receive ITI-007.

An urgent need exists for new treatments of schizophrenia that are effective against a broad range of symptoms and free of limiting safety issues. ITI-007 (Lumateperone tosylate)is an experimental medication that affects brain proteins that is being developed as a schizophrenia treatment. ITI-007 appeared to work similarly to an FDA approved medication for schizophrenia (risperidone) in a recently published study. The purpose of this study is to offer open label ITI-007 treatment to patients who either poorly respond or poorly tolerate approved medications. A discussion about clozapine will occur during the consent process.

There is no compensation for the study, however you can be reimbursed up to $50 per visit for study related expenses (e.g., travel, food, etc). You may be asked to provide receipts for reimbursement of expenses.

If you have questions or if you would like to participate in this study call 646-774-8496 or e-mail melissa.conant@nyspi.columbia.edu.

Data collection for this study began in March 2019 and is scheduled to end in March 2021.

Improving Cognition via Exercise in Schizophrenia

The goal of this study is to examine the impact of exercise training on cognition, daily functioning, and biomarkers of cognitive change in people diagnosed with schizophrenia and related disorders.

Following an initial research assessment, participants will be assigned by chance to participate in either aerobic exercise training or stretching-and-toning exercise training. Participants in both groups will take part in a 12-week, 3-times per week, 1-hour training program, in addition to their regular psychiatric and/or medical care. All training will be led by a certified trainer in a small group setting. Participants may continue to be treated by their current psychiatrist and/or other mental health clinicians during the study. 

Research assessments will be administered at baseline, and after 6- and 12-weeks of training.  These include diagnostic, clinical and cognitive assessments (interviews, questionnaires, cognitive tasks); fitness assessments and physical activity monitoring; and providing urine and blood samples.

Additional information is available about the study is available at: https://clinicaltrials.gov/ct2/show/NCT03270098?term=NCT03270098&rank=1

Data collection for the study began in May 2018 and is expected to last ~3 years.

Is the study therapeutic? – Yes.

Is the study funded? – Yes, the study is funded by a federal grant from the National Institute of Mental Health, Bethesda, MD (NIMH, Grant #: R01MH110623)

Would subjects be paid? – Eligible participants may receive up to $260 for the completion of the study procedures and research assessment. Participants will also receive reimbursement for travel expenses associated with attending the research assessments and the weekly exercise sessions. 

Contact Information – Interested participants should contact Dr. Luz Ospina, Study Director, at 212-585-4647 orluz.ospina@mssm.edu .

Post expires May 2021.

The primary objective of this study is to understand how brain anatomy relates to function and health. This study is funded by the National Institute of Mental Health and is conducted at New York University School of Medicine, Departments of Radiology and Psychiatry.

We are recruiting 18-30 year old participants who have been diagnosed with schizophrenia or bipolar disorder in the last five years. An initial telephone screening and clinical interview will establish eligibility for the study.

The study involves:

• Clinical assessment
• MRI scanning
• Blood draw
• Cognitive Assessment

This is a non-therapeutic study that does not involve treatment and does not interfere with any ongoing treatments. If eligibility criteria are met, a compensation of $160 will be provided at the completion of the study.

For more information please contact: mariana.lazar@nyumc.org or 212 263-3348.

There is no expiration date for the post at this time.

Do you have a loved one between the ages of 13-17 who has been diagnosed with Schizophrenia or has symptoms of Schizophrenia? Are you interested in joining a clinical research study that may increase our understanding of the disease?

This study is designed to evaluate the safety and efficacy of an investigational drug, called brexpiprazole, for adolescent patients diagnosed with Schizophrenia. The study will compare this medication with an active control (ABILIFY® (aripiprazole)) and placebo.

In order for your child to take part in the clinical research study, you will need to review the full checklist of criteria – found on the eligibility page. Some of the basic criteria that must be met are:

• Be 13-17 years old
• Have a diagnosis or symptoms of schizophrenia that has been confirmed by their doctor
• Do not have a diagnosis of autism, bipolar disorder, schizoaffective disorder, pervasive developmental disorder (PDD), OCD, or PTSD that has been the primary focus of treatment within 3 months of screening.
• Do not have a history of seizures, epilepsy, stroke, or head trauma.

Other requirements will be reviewed in detail with you by the Study Center staff, if your child meets the requirements above and attends a screening visit.

Click here to begin screening.

This study is looking at whether an investigational medication called BI 409306 is safe and effective in reducing the early symptoms of psychosis. The goal of this study is to increase treatment options available for people experiencing the early symptoms of psychosis.

Participants may be eligible for this study if they are:

• 16-30 years old
• Experiencing early symptoms of psychosis
• Have not yet experienced a first episode of psychosis

If you have questions or would like more information, please refer to the trial website (https://1289-0032study.com)